


























In human breast cancer patients, the hormone estrogen 
and its main receptor (ESR1), are key drivers of tumor 
initiation, cancer progression and ultimately metastasis 
[1-4].   As  a  consequence,  targeted  therapies,  such  as 
 
Tamoxifen, were first developed to inhibit estrogen 
receptor signaling, in ER(+) breast cancer cells [5]. 
Historically, Tamoxifen represents one of the earliest 
forms of targeted therapy and was first clinically trialed 
in the 1970’s, at the Christie Hospital in Manchester, 
UK [6-8].  
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the clinical development of  resistance  to hormonal  therapies,  such as Tamoxifen.   For example,  the  somatic
mutation Y537S has been specifically associated with acquired endocrine resistance. Briefly, we recombinantly‐
transduced MCF7 cells with a lentiviral vector encoding ESR1 (Y537S). As a first step, we confirmed that MCF7‐




also Tamoxifen‐resistant. Metabolic  flux analysis of Y537S  cells  revealed a hyper‐metabolic phenotype, with
significantly  increased  mitochondrial  respiration  and  high  ATP  production,  as  well  as  enhanced  aerobic
glycolysis.   Finally,  to understand which molecular  signaling pathways  that may be hyper‐activated  in Y537S
cells, we performed unbiased  label‐free proteomics analysis. Our  results  indicate  that TIGAR over‐expression
and  the  Rho‐GDI/PTEN  signaling  pathway  appear  to  be  selectively  activated  by  the  Y537S  mutation.
Remarkably,  this profile  is nearly  identical  in MCF7‐TAMR cells;  these cells were  independently‐generated  in
vitro,  suggesting a highly conserved mechanism underlying Tamoxifen‐resistance.  Importantly, we  show  that
the Y537S mutation is specifically associated with the over‐expression of a number of protein markers of poor
clinical outcome (COL6A3, ERBB2, STAT3, AFP, TFF1, CDK4 and CD44).  In summary, we have uncovered a novel
metabolic  mechanism  leading  to  endocrine  resistance,  which  may  have  important  clinical  implications  for
improving patient outcomes.  
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Unfortunately, however, endocrine therapy ultimately 
fails in a significant number of patients on long-term 
anti-estrogen therapy, due to the acquired emergence of 
drug-resistance. The resulting treatment failure often 
has dire consequences for the patient, with the 
emergence of tumor recurrence and distant metastasis, 
resulting in poor clinical outcomes.  
 
If we are going to successfully prevent or reverse 
treatment failure, we need to know the underlying 
mechanism(s) by which ER(+) tumor cells can success-
fully escape the effects of hormonal therapy. Until 
recently, the prominent role of somatic mutations in the 
estrogen receptor, in conferring resistance to endocrine 
therapy, has remained largely unappreciated [4, 9]. 
 
These somatic mutations can significantly change the 
conformation and functional activity of the estrogen 
receptor, effectively locking it a constitutively-activated 
state [10]. Two of the most common mutations, namely 
Y537S and D538G, both allow the estrogen receptor to 
bind coactivators, in the absence of the estrogen ligand, 
resulting in a constitutively-active receptor [11-13]. 
 
Here, we mechanistically studied the phenotypic effects 
of the Y537S mutation on MCF7 cells in culture. For 
this purpose, we created a genetic model in MCF7 cells 
by stably over-expressing the ESR1 cDNA carrying the 
Y537S mutation. Importantly, we show that the Y537S 
mutation confers a hyper-active phenotype, due to the 
metabolic re-programming of mitochondrial function 
and the glycolytic pathway, resulting in increased ATP 
production and resistance to apoptosis, effectively 
protecting CSCs from the anti-mitochondrial effects of 
Tamoxifen.  
 
Interestingly, it is well-known that Tamoxifen also 
functions as an inhibitor of mitochondrial complex I 
activity [14, 15]. Therefore, it is perhaps not surprising 
that Tamoxifen resistance could be achieved, by the 
ability of the Y537S mutation to effectively augment 
mitochondrial “power”.  
 
In support of this hypothesis, high levels of key 
mitochondrial markers, including complex I proteins, 
are specifically-associated with Tamoxifen-resistance in 




Generating a genetic model of Tamoxifen-resistance: 
MCF7-Y537S cells 
 
Somatic mutations of the human estrogen receptor alpha 
(ESR1) have been directly implicated in the patho-
genesis of hormonal therapy resistance in human breast 
cancer patients [1, 9]. However, the exact mecha-
nism(s) by which these ESR1 mutations induce 
Tamoxifen-resistance remains largely unknown. To 
begin to dissect how these mutations phenotypically 
confer drug resistance, we chose to construct an in vitro 
genetic model, using MCF7 cells, an ER(+) breast 
cancer cell line.  
 
Briefly, MCF7 cells were transduced with a lentiviral 
vector carrying the Y537S mutation of ESR1 and 
positive “pools” of cells were selected, using a puro-
mycin resistance cassette. Four other isogenic MCF7 
cells lines were also generated in parallel, which served 
as negative controls for these experiments: ESR1 (WT 
and Y537N), ErbB2 and empty-vector (EV).  
 
To directly determine the validity of our model system, 
MCF7-Y537S cells were cultured for 5 days in the 
presence of Tamoxifen (1 µM) to assess its affect on 
cell viability.  Importantly, Figure 1 shows that only 
MCF7-Y537S cells manifest a Tamoxifen-resistance 
phenotype, while all the other MCF7 cell lines tested 


































Figure  1.  Lentiviral  transduction with  the  ESR1  (Y537S)
mutation  is  sufficient  to  stably  confer  Tamoxifen‐
resistance  in  MCF7  cell  monolayers:  Effects  on  cell
viability. Briefly, MCF7 cells were stably‐transduced with either
ESR1  (WT,  Y537S,  or  Y537N)  or  ErbB2  (HER2),  to  genetically
create  a  clinically  relevant  model  of  hormone  therapy  resis‐
tance.  Vector  alone  control  MCF7  cells  were  generated  in
parallel  (empty  vector;  EV;  p‐EV‐105‐puroR),  as  a  negative
control.  Importantly,  note  that MCF7‐Y537S  cells  clearly  show
resistance to 4‐OHT  (1 µM). The SRB assay was performed as a
measure of cell viability and the experiment was carried out for
5  days.  In  contrast,  4‐OHT  has  significant  inhibitory  effects  on
the viability of the other MCF7 cell lines. ** p<0.005. 












































These findings provide the necessary evidence for the 
use of MCF7-Y537S cells as a valid genetic model of 
Tamoxifen-resistance.  Since the Y537N mutation did 
not drive Tamoxifen resistance in this context, other 
micro-environmental factors may be needed to observe 
this phenotype.  
 
Y537S drives resistance to Tamoxifen-induced 
apoptosis, enhancing mammosphere formation 
 
An additional mechanism by which the Y537S mutation 
may contribute to Tamoxifen-resistance is its potential 












































To test this hypothesis, we first assessed potential 
effects on CSC propagation, using the mammosphere 
assay. In the absence of Tamoxifen, the Y537S muta-
tion had no effect on mammosphere formation. 
However, in the presence of Tamoxifen, the Y537S 
mutation significantly promoted mammosphere forma-
tion, by nearly 2-fold. However, similar effects were 
also observed with the wild-type ESR1. Quantitation of 
these results is presented in Figure 2 and representative 
images are shown in Figure 3.  
 
One mechanism by which the Y537S mutation may 
promote  mammosphere  formation  in  the  presence  of  
Figure 2. MCF7‐Y537S cells are resistant to the inhibitory effects of Tamoxifen on mammosphere formation:
Quantitation.  Mammosphere  formation  assays  were  carried  out  for  5  days,  in  6  well‐plates,  under  low‐attachment
conditions. All the transfected MCF7 cell lines were grown as mammospheres. Note that 72h of pre‐treatment with 4‐OHT




























































Tamoxifen is by conferring resistance to apoptosis. In 
direct support of this hypothesis, Figure 4 highlights 
that the Y537S mutation significantly reduces annexin-
V staining in the presence of Tamoxifen, as revealed by 
FACS analysis, consistent with apoptosis resistance.  
 
As a second independent marker of “stemness”, we next 
assessed the levels of ALDH activity, by using 
ALDEFLUOR as a fluorescent probe, during FACS 
analysis. Briefly, all the transfected MCF7 cell lines 




















































effects  of  Tamoxifen  during  mammosphere  formation:
Representative  images.  Note  that  overall  4‐OHT  (1  µM)
treatement reduces mammosphere formation; however, MCF7‐
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prepare a single-cell suspension. Importantly, only 
Y537S cells showed significant increases (>3-fold) in 
ALDH activity (Figure 5A).  Also, note that treatment 
with 4-OHT (1 µM) inhibits ALDH activity in empty 
vector (EV) control cells, but not in MCF7-Y537S cells 
(Figure 5B). This observation is consistent with the idea 
that increased “stemness”, driven by the Y537S 
mutation, helps to confer tamoxifen-resistance.  
 
Y537S confers a hyper-metabolic phenotype, with 
increased mitochondrial function and ATP 
production, elevated mitochondrial biogenesis and 
enhanced glycolysis 
 
We next hypothesized that one phenotypic mechanism 
by which the Y537S mutation may confer Tamoxifen-







































As a consequence, we subjected Y537S cells to 
metabolic phenotyping with the Seahorse XFe96 
metabolic flux analyzer. Figures 6 and 7 show the 
results of these studies. Importantly, we observed that 
the Y537S mutation significantly increases the 
mitochondrial oxygen consumption rate (OCR) and 
ATP production, by >3-fold and ~2-fold, respectively. 
Similarly, the Y537S mutation also substantially 
elevated glycolysis and the glycolytic reserve capacity, 
by nearly 2-fold. Therefore, MCF7-Y537S cells are 
hyper-metabolic, with enhanced mitochondrial and 
glycolytic function.  
 
This elevated mitochondrial function may be due to 
increased mitochondrial biogenesis. Figure 8 illustrates 
that the Y537S mutation increases both mitochondrial 
mass and mitochondrial membrane potential, as 












































in  empty  vector  (EV)  control  cells,  but  not  in MCF7‐Y537S  cells.  *  p<  0.05;  ***  p<  0.0005;  ns  =  not  significant,  as
evaluated by Student’s t test. (Panel A) ALDH activity; (Panel B) ALDH activity, with and without treatment with 4‐OHT.
This observation is consistent with the idea that increased stemness helps to confer tamoxifen‐resistance.   
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This approach allowed us to calculate the activity/mass 
ratio, which was also increased in MCF7-Y537S 
cells.  
 
Remarkably, previous studies with TAMR cells showed 
similar metabolic re-programming, with increased OCR 
and ATP production, as well as elevated mitochondrial 
biogenesis [17]. TAMR cells are an MCF7-based model 
of Tamoxifen-resistance, generated via the long-term 
culture of MCF7 cells in the presence of increasing 
concentrations of Tamoxifen [17, 18].  
 
Proteomics analysis reveals that the Y537S mutation 
up-regulates key metabolic targets and hyper-
activates Rho-GDI/PTEN signalling in MCF7 cells.  
 
To further validate the hyper-metabolic phenotype that 
we observed via Seahorse analysis, we next subjected 
MCF7-Y537S cells to unbiased label-free proteomics 
analysis.  For example, MCF7-Y537S cells were 
compared to MCF7-ESR1(WT) and empty-vector alone 



































Relative to ESR1(WT), the ESR1(Y537S) mutant 
showed dramatic increases in 33 mitochondrial proteins, 
consistent with increased mitochondrial oxygen con-
sumption (OXPHOS) and elevated mitochondrial bio-
genesis (Supplementary Table S1).  Several key com-
ponents of Complex I were also up-regulated 
(NDUFB10, NDUFV1, NDUFA5). In addition, the 
ESR1(Y537S) mutant showed significant elevations in 
glycolytic and PPP enzymes (Supplementary Table S2), 
including TIGAR, which has been previously shown to 
be sufficient to confer Tamoxifen-resistance. In this 
context, TIGAR expression was infinitely up-regulated 
by the ESR1(Y537S) mutation. Interestingly, the 
ESR1(Y537S) mutant was specifically associated with 
high levels of seven markers of poor clinical outcome 
(COL6A3, ERBB2, STAT3, AFP, TFF1, CDK4, CD44) 
(Supplementary Table S3). Thus, a single point 
mutation in the estrogen receptor can drive extensive 
metabolic re-programming. 
 
We also compared the profile of MCF7-Y537S cells 




































and  ATP  production.  The  Seahorse  XFe96 metabolic‐flux  analyzer  was  employed  to  determine  mitochondrial
function  in  all  of  the MCF7  cell  transfectants,  after  48  hours  of  pre‐treatment with  4‐OHT  (1  µM).  (Panel  A)  A
representative line graph of 3 independent experiments is shown (+/‐ SEM). (Panels B, C and D) Note that respiration
(basal  and  maximal),  as  well  as  ATP  levels,  were  significantly  increased  in  MCF7‐Y537S  and  MCF7‐Y537N  cells.
However, MCF7‐Y537S cells showed that largest increases. ** p < 0.001; **** p < 0.00001; ns = not significant. 




































Tamoxifen-resistant cell line. TAMR cells were 
originally derived by chronically culturing MCF7 cells 
in low levels of Tamoxifen, and then increasing its 
concentration in a step-wise fashion over time. Remar-
kably, these extensive comparisons revealed that a Rho-
GDI/PTEN signaling pathway appears to be hyper-
activated in both of these Tamoxifen-resistant cell lines 
(Figure 9; see also Figures S1 to S4).  
 
Clinical relevance of metabolic marker proteins 
induced by the Y537S mutation: Predicting the 
response to endocrine therapy.  
 
To further validate the clinical relevance of our 
findings, we next assessed whether the “metabolic 
targets” that we identified in MCF7-Y537S cells were 
also transcriptionally upregulated in human breast 
cancer cells in vivo. For this purpose, we employed a 
published clinical data set of N=28 breast cancer 





































laser-capture micro-dissection (25), to physically 
separate epithelial cancer cells from their adjacent 
tumor stroma. Supplementary Table S4 presents a 
summary of these findings.  Overall, many of the 
“metabolic targets” that we identified were also 
transcriptionally elevated in human breast cancer cells 
in vivo.  
 
Next, we determined if the metabolic proteins up-
regulated by the Y537S mutation in MCF7 cells have 
any clinical prognostic value, for predicting the onset of 
tamoxifen-resistance in breast cancer patients. For this 
purpose, we examined their mRNA expression levels in 
a cohort of ER(+)-patients. This population consisted of 
152 patients, with the most common sub-type of breast 
cancer (Luminal A), with local lymph-node (LN) 
metastasis at diagnosis, specifically undergoing endo-
crine therapy (mostly Tamoxifen), without any form of 
chemotherapy.   
Figure 7. MCF7‐Y537S  cells  show a  significant  increase  in extracellular acidification  rate  (ECAR) and
glycolysis levels. The Seahorse XFe96 metabolic‐flux analyzer was employed to determine the metabolic function
of all transfected cells after 48 hours of treatment with 4‐OHT (1 µM).   (Panel A) A representative  line graph of 3
independent experiments  is shown (+/‐ SEM). (Panel B) Glycolysis was significantly  increased only  in MCF7‐Y537S
cells and reduced in MCF7‐ErbB2 and MCF7‐ESRI cells. (Panel C) Glycolytic capacity was significantly increased only
in  MCF7‐Y537S  and  reduced  in  MCF7‐ErbB2  and  MCF7‐ESRI  cells.  (Panel  D)  Glycolytic  reserve  capacity  was
significantly increased only in MCF7‐Y537S cells. ** p < 0.001; *** p 0.0001; **** p < 0.00001; ns = not significant. 







































In this setting, Tamoxifen-resistance manifests itself 
clinically, as either i) tumor recurrence or ii) distant 
metastasis. As such, Kaplan-Meier (K-M) curves were 
constructed using recurrence-free survival (RFS) or 
distant-metastasis free survival (DMFS), over a period 
of 10 to 15 years of follow-up.   Hazard-ratios (HR) and 
p-values (log-rank test) were calculated and are as 
shown in Supplementary Tables S5 - S8.  
 
More specifically, Supplementary Tables S5 and S7 
highlight the mitochondrial mRNA transcripts associ-
ated with tumor recurrence and distant metastasis, 
respectively. Similarly, Supplementary Tables S6 and 
S8 show the glycolytic and PPP enzyme mRNA trans-
cripts associated with poor clinical outcomes.  
 
Note that the mRNA levels of key metabolic proteins in-







































ment failure during endocrine therapy, highlighting their 
clinical relevance. These findings provide a direct functi-
onal link between the Y537S mutation, metabolic re-pro-




Understanding how the Y537S mutation promotes 
Tamoxifen-resistance 
 
Somatic mutations in the estrogen receptor gene are 
specifically associated with the onset and development 
of hormone therapy resistance in human breast cancer 
patients [1, 3, 5]. In particular, the Y537S mutation 
drives endocrine resistance by maintaining the estrogen 
receptor in the constitutively activated state, resulting in 
an aggressive clinical phenotype, leading to tumor 
recurrence and distant metastasis [19, 20].  
Figure 8. Mitochondrial biogenesis and membrane potential are increased in MCF7‐Y537S cells, in the presence
of 4‐OHT.   To determine  the possible effects of  the Y537S mutation on mitochondrial biogenesis and membrane potential,
MCF7‐Y537S  cells  were  subjected  to  flow‐cytometry,  using  MitoTracker  probes.  FACS  analysis  was  carried  out  on  MCF7
transfected  cells  after  pre‐treatment with  4‐OHT.  (Panels A  and B) Note  that MCF7‐Y537S  and MCF7‐Y537SN  cells  show  a
































In this report, we generated a new cellular model of 
endocrine therapy resistance, by modeling the gain-of-
function effects afforded by the acquisition of the 
Y537S mutation. For this purpose, using a lentiviral 
vector, we inserted the cDNA encoding the mutated 
ESR1 (Y537S) gene into MCF7 human breast cancer 
cells. As negative controls, a series of other isogenic 
MCF7 cell lines, harboring the wild-type estrogen 
receptor and the empty-vector (EV), were also 
generated. Importantly, we first functionally validated 
that expression of the ESR1 (Y537S) mutant was indeed 
sufficient to experimentally confer Tamoxifen-
resistance, relative to other control cell lines, tested 
side-by-side.  Remarkably, the Y537S mutant conferred 
drug-resistance to Tamoxifen-induced cell apoptosis, 
allowing the efficient formation of 3D tumor spheroids, 
even in the presence of Tamoxifen.  
 
We also tested the hypothesis that the Y537S mutation 
confers an abnormal metabolic phenotype, reflecting a 
form of gene-induced metabolic re-programming. In 
particular, by using the Seahorse XFe96 metabolic flux 
analyser, we determined the effects of the Y537S 
mutation on the i) oxygen consumption rate (OCR) and 
ii) the extracellular acidification rate (ECAR), as well as 
ATP production. Interestingly, the Y537S mutation 
resulted in a hyper-metabolic state, accompanied by 
elevated rates of mitochondrial respiration, enhanced 
ATP levels and increased glycolysis. Consistent with 



























chondrial mass and membrane potential, likely 
reflecting an increase in mitochondrial biogenesis.  
 
Unbiased proteomics analysis was carried out to 
identify the key metabolic targets that were increased by 
the Y537S mutation. Ultimately, over 30 nuclear-
encoded mitochondrial proteins were found to be over-
expressed, as well as greater than 9 enzymes linked to 
glycolysis and the pentose-phosphate pathway.  
 
Interestingly, the Y537S mutation was also linked to the 
over-expression of a number of protein markers of poor 
clinical outcome (TIGAR, COL6A3, ERBB2, STAT3, 
AFP, TFF1, CDK4, CD44).  Ingenuity Pathway 
Analysis (IPA) independently demonstrated that the 
proteomic profile of MCF7-Y537S cells is very similar 
to MCF7-TAMR cells, another Tamoxifen-resistant cell 
line created by chronic exposure to Tamoxifen [17]. 
Both cell lines show the hyper-activation of a Rho-
GDI/PTEN signaling pathway.  These novel mecha-
nism(s) driving Tamoxifen-resistance clearly have 
important implications for significantly improving 
clinical outcomes for breast cancer patients.   
 
Linking the Y537S mutation to TIGAR 
 
TIGAR (TP53-inducible glycolysis and apoptosis 
regulator) was originally discovered as a p53-regulated 
gene [21, 22]. However, TIGAR shows striking protein 
sequence similarity to the glycolytic enzyme that de-
Figure  9.  Ingenuity  Pathway  Analysis  (IPA)  of  proteomics  data  sets  obtained  from  two  distinct
Tamoxifen‐resistant  breast  cancer  cell  lines  (TAMR  vs.  MCF7‐Y537S  cells).    The  canonical  signaling
pathways predicted to be altered are shown. Briefly, both 4‐OHT resistant cell lines (TAMR vs. MCF7‐Y537S) were
compared  to each other, as well as with MCF7 control cells, all grown as monolayers. HeatMaps of  the  top 10
regulated canonical pathways are shown. A positive z‐score  (Orange) points towards the activation of a signalling
pathway, while a negative z‐score (Blue) indicates the inhibition of a pathway (p < 0.05 and cutoff z‐score ± 2). 
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grades fructose-2,6-bisphosphate, especially within its 
bisphosphate domain [23, 24]. Therefore, TIGAR likely 
functions as an inhibitor of glycolysis, but also 
stimulates the up-regulation of the pentose-phosphate 
pathway (PPP) and can confer protection against 
apoptosis [22, 23].  
 
Interestingly, we have previously shown that the 
expression of TIGAR is indeed sufficient to confer 
Tamoxifen-resistance [25]. Therefore, since the expres-
sion of TIGAR is infinitely up-regulated by expression 
of the Y537S mutation, this could also help explain the 
mechanism by which Y537S confers Tamoxifen-
resistance. 
 
Association of the Y537S mutation with COL6A3 
 
Collagen VI is an extracellular matrix protein that has 
been previously associated with tumor progression and 
distant metastasis [26].  Since the expression of 
COL6A3 is infinitely up-regulated by expression of the 
Y537S mutation, this could also explain how Y537S 
confers Tamoxifen-resistance. Tumor-specific isoforms 
of COL6A3 have been reported [27].  
 
Metabolic markers induced by the Y537S mutation 
determine the response to endocrine therapy 
 
Finally, we determined if the metabolic proteins up-
regulated by the Y537S mutation in MCF7 cells have 
any clinical prognostic value, for predicting the onset of 

























tumor recurrence and/or distant metastasis). 
Importantly, our results indicate that the mRNA levels 
of key metabolic proteins induced by the Y537S muta-
tion positively predict treatment failure during endo-
crine therapy, highlighting their clinical relevance. 
These findings provide a direct functional link between 
the Y537S mutation, metabolic re-programming and the 
clinical response to endocrine therapy.  
 
Potential metabolic therapies for targeting 
Tamoxifen-resistance 
 
As our current results demonstrate that MCF7 cells 
harboring the Y537S mutation show characteristic 
features of metabolic re-programming and increased 
“stemness”, this suggests that patients harboring the 
Y537S mutation could ultimately benefit from treatment 
with metabolic therapeutics, specifically targeting i) 
mitochondrial metabolism, ii) glycolysis and iii) 
NAD(+) recycling (enumerated in Table 1). In previous 
studies, we have shown that several FDA-approved 
antibiotics (Doxycycline, Tigecycline, Azithromycin, 
Pyrvinium pamoate, Atovaquone and Bedaquiline) and 
natural products (Actinonin, CAPE, Berberine, 
Brutieridin and Melitidin) can all be used to effectively 
target mitochondria in ER(+) breast cancer stem cells 
(CSCs) [28-34]. Moreover, glycolysis inhibitors, such 
as Vitamin C (Ascorbic acid), 2-deoxy-glucose (2-DG), 
Silibinin, and Stiripentol, were also effective at 
targeting ER(+) breast CSCs [33, 34].  In addition, our 
clinical pilot study (Phase II) has already shown that 


























1. Mitochondrial Inhibitors     References 
• Doxycycline       [28,29,30] 
• Tigecycline      [28,30] 
• Azithromycin       [28,30] 
• Pyrvinium pamoate      [28,30] 
• Atovaquone         [30,31] 
• Bedaquiline        [30,32] 
• Actinonin       [30,33] 
• CAPE (Caffeic Acid Phenyl Ester)    [30,33] 
• Berberine       [30,34] 
• Brutieridin & Melitidin (isolated from Bergamot)   [30,37] 
  
2. Glycolytic Inhibitors  
• Vitamin C (Ascorbic acid)     [30,33,34] 
• 2-Deoxy-Glucose (2-DG)      [30,33,34] 
• Silibinin       [30,33] 
• Stiripentol       [30,33,34] 
  
3. NAD(+) Inhibitors  
• FK-866       [30,33] 
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cancer patients, for significantly reducing CSCs (by up 
to 66.67 %), with a response rate of nearly 90 % [35]. 
We anticipate that MCF7 cells recombinantly over-
expressing the ESR1-Y537S mutation will provide a 
new fruitful isogenic model for the metabolic screening 
of these and other candidate drugs, for combating 


























In conclusion, here we have generated a genetic model 
of Tamoxifen-resistance in MCF7 cells, by over-
expressing a somatic mutation of the estrogen receptor, 
namely ESR1-Y537S.  Our results directly show that 
the Y537S mutation confers Tamoxifen-resistance by 
driving re-programming towards a hyper-active 
metabolic phenotype, characterized by high levels of 
OXPHOS and mitochondrial biogenesis, as well as 
elevated levels of glycolysis (Figure 10). This contention 
is supported by genetic evidence, quantitative metabolic 
flux analysis, flowcytometry, unbiased proteomics and 
computer-assisted bioinformatics analysis. These 
findings have important trans-lational implications for 
preventing treatment failure in ER(+) breast cancer 
patients currently taking hormonal therapies.  
 




The human breast cancer cell line (MCF7) was obtained 
commercially from the ATCC.  The cell line  was  main- 
tained in Dulbecco’s Modified Eagle Medium 
(DMEM; GIBCO) supplemented with 10% HiFBS, 1% 
Glutamax and 1% Penicillin-Streptomycin, at 37°C in 
5% CO2.  
 
Lentiviral gene transduction 
 
Lentiviral vectors for our gene expression studies were 
all custom-built to our specifications by GeneCopoeia. 
The cDNA’s encoding ESR1 (catalogue number: 
A0322; NM_001122742.1) or ErbB2 (catalogue 
number: Z2866; NM_004448.2) were inserted into the 
expression vector Lv-105-puroR, containing a 
puromycin gene resistance cassette. Two vectors encod-
ing ESR1 mutants (Y537S and Y537N) were also 
generated by site-directed mutagenesis and were con-
firmed by DNA-sequencing. Packaging cells (293Ta) 
and all reagents were purchased from GeneCopoeia 
Inc., respectively. After 48 hours of seeding and culture, 
293Ta packaging cells were transfected with lentiviral 
vectors encoding ESR1, ESR1-Y537S, ESR1-Y537N, 
ErbB2 or empty vector EV (EX-NEG-Lv105), using 
Lenti-PacTM HIV Expression Packaging Kit, according 
to the manufacturer’s instructions. Two days post-
transfection, lentivirus-containing culture medium was 
passed through a 0.45 μm filter and added to the target 
cells (MCF7 cells) in the presence of 5 μg/ml 
Polybrene. Infected cells were selected with a 
concentration of 1.5 μg/ml of puromycin [17]. These 
cell lines were generated, while working at the 
University of Manchester, at the Paterson Institute (MF, 
FS and MPL). Expression of exogenous ESR1 
constructs did not detectably alter the expression of 
endogenous ESR1, as assessed by Western blot 
analysis. 
 
Sulfo-rhodamine B (SRB) assay 
 
SRB measures total biomass by staining cellular 
proteins. After 5 days treatment with of 4-OH-
Tamoxifen (4-OHT, Sigma , cells were fixed in 10% 
trichloroacetic acid (T9159, Sigma) for 1h at 4°C, 
stained with SRB (S9012, Sigma) for 15 minutes, and 
washed 3 times with 1% acetic acid (27225, Sigma). 
The incorporated dye was solubilized with 10 mM Tris-
HCl, pH 8.8 (T1503, Sigma). Absorbance was spectro-
photometrically measured at 540 nm in a FluoStar 
Omega plate reader (BMG Labtech). Background 
measurements were subtracted from all values. 
 
MCF7 3D-mammosphere formation  
 
A single cell suspension was prepared using enzymatic 
(1x Trypsin-EDTA, Sigma Aldrich, #T3924), and 
manual disaggregation (25 gauge needle), to create a 
single cell suspension. Cells were plated at a density of 
Figure  10.  Schematic  diagram  summarizing  the  role  of
the  ESR1‐Y537S  mutation  in  driving  Tamoxifen‐
resistance.   Note  that  the  Y537S mutation  induces metabolic
reprogramming, with the hyper‐activation of both mitochondrial
and glycolytic energetic pathways.  
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500 cells/cm2 in mammosphere medium (DMEM-F12 + 
B27 + 20 ng/ml EGF + PenStrep) under non-adherent 
conditions, in culture dishes pre-coated with (2-
hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932), called “mammosphere plates” [36]. Then, the 
cells were pre-treated for 72 hours with 1µM of 4-OH-
Tamoxifen. Vehicle alone (DMSO) control cells were 
processed in parallel. Afterwards, they were trypsined 
and seeded in mammosphere plates. Cells were grown 
for 5 days and maintained in a humidified incubator at 
37°C. After 5 days of culture, 3D-spheres >50 μm were 
counted using an eye piece (“graticule”), and the 
percentage of cells plated which formed spheres was 
calculated and is referred to as percent mammosphere 
formation, and was normalized to one (1 = 100% MSF) 
[37]. 
 
ALDEFLUOR assay  
 
ALDH activity was assessed in all the MCF7 stable cell 
lines generated. The ALDEFLUOR kit (StemCell 
technologies, Durham, NC, USA) was used to isolate 
the population with high ALDH enzymatic activity by 
FACS (Fortessa, BD Bioscence).  Briefly, after 5 days 
of culture, the mammospheres were harvested, tryp-
sinized and syringed to generate a single-cell sus-
pension.  Then, they were incubated in 1ml of 
ALDEFLUOR assay buffer containing ALDH substrate 
(5 μl/ml) for 40 minutes at 37°C. In each experiment, a 
sample of cells was stained under identical conditions 
with 30 mM of diethylaminobenzaldehyde (DEAB), a 
specific ALDH inhibitor, as a negative control. The 
ALDH-positive population was established, according 
to the manufacturer’s instructions and was evaluated 
using 30.000 cells. An ALDEFLUOR-positive signal 





Cell death was quantified by flow cytometry using 
propidium iodide (PI) and Annexin V-FITC [16]. 
Briefly, 1,5 x 105  all the transfected cells were plated in 
6 multiwell plate in complete media supplemented with 
10% HiFBS. Next day, cells were treated with 1µM of 
4-OH-Tamoxifen (4-OHT) for 48h and 72h. Vehicle 
alone (DMSO) for control cells were processed in 
parallel. After 48 hours, cells were harvested and 
washed in cold phosphate-buffered saline (PBS). Cells 
were recentrifuged and supernatants were discarded. 
Then, cells were re-suspended in 100 µl of annexin-
binding buffer. Then, the annexin–FITC conjugate (5 
μl) and PI (1 μL) were added and incubated in the dark 
at room temperature for 15 min. After the incubation 
period, reaction was stopped by adding 400 μL of 
annexin-binding buffer. Cells were then analyzed by 
flow cytometry using a PE Texas Red signal detector 
for PI staining and a FITC signal detector to detect 
Annexin V binding. 30,000 events were recorded by 
FACS using Fortessa BD. Results are the average of 
three experiments that were performed in triplicate, 
three times independently. 
 
Seahorse XFe96 metabolic flux analysis 
 
Real-time oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR) rates in all 
transfected cells treated with 1µM of 4-OHT for 48h 
were determined using the Seahorse Extracellular Flux 
(XFe96) analyzer (Seahorse Bioscience, USA) [38]. 
Briefly, 1,5 x 104 cells per well were seeded into XFe96 
well cell culture plates, and incubated overnight to 
allow cell attachment. Then, cells were treated with 
1µM of 4-OHT for 48h. Empty vector (EV) control 
cells were processed in parallel. After 48 hours of 
incubation, cells were washed in pre-warmed XF assay 
media (or for OCR measurement, XF assay media 
supplemented with 10mM glucose, 1mM Pyruvate, 
2mM L-glutamine and adjusted at 7.4 pH). Cells were 
then maintained in 175 µL/well of XF assay media at 
37°C, in a non-CO2 incubator for 1 hour. During the 
incubation time, we loaded 25 µL of 80mM glucose, 
9µM oligomycin, and 1M 2-deoxyglucose (for ECAR 
measurement) or 10µM oligomycin, 9µM FCCP, 10µM 
rotenone, 10µM antimycin A (for OCR measurement), 
in XF assay media into the injection ports in the XFe96 
sensor cartridge [31, 32]. Measurements were 
normalized by protein content (Bradford assay). Data 
sets were analyzed using XFe96 software and GraphPad 
Prism software, using one-way ANOVA and Student’s 
t-test calculations. All experiments were performed in 
quintuplicate, three times independently. 
 
Mitochondrial staining  
 
Mitochondrial activity was assessed with MitoTracker 
Orange (#M7510, Invitrogen), whose accumulation in 
mitochondria is dependent upon membrane potential. 
Mitochondrial mass was determined using MitoTracker 
Deep-Red (#M22426, Invitrogen), localizing to 
mitochondria regardless of mitochondrial membrane 
potential [39, 40]. MCF7 transfected cells were seeded 
for 48 hours. MCF7-EV control cells were processed in 
parallel. After 48 hours, cells were incubated with pre-
warmed MitoTracker staining solution (diluted in 
PBS/CM to a final concentration of 10 nM) for 30-60 
minutes at 37°C. All subsequent steps were performed 
in the dark. Cells were washed in PBS, harvested, and 
re-suspended in 300 μL of PBS/CM. Cells were then 
analyzed by flow cytometry. Data analysis was 
performed using FlowJo software. 
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Label-free unbiased semi-quantitative proteomics 
analysis 
 
Cell lysates were prepared for trypsin digestion by 
sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled 
to an Ultimate 3000 RSLCnano system (Thermo 
Scientific, formerly Dionex, The Netherlands) [41]. 
Xcalibur raw data files acquired on the LTQ-Orbitrap 
XL were directly imported into Progenesis LCMS 
software (Waters Corp., Milford, MA, formerly Non-
linear dynamics, Newcastle upon Tyne, UK) for peak 
detection and alignment. Data were analyzed using the 
Mascot search. Five technical replicates were analyzed 
for each sample type.  
 
Ingenuity pathway analysis (IPA) 
 
Unbiased interrogation and analysis of our proteomic 
data sets was carried out by employing a bioinformatics 
platform, known as Ingenuity Pathway Analysis (IPA) 
(Ingenuity systems, http://www.ingenuity.com). IPA 
assists with data interpretation, via the grouping of 
differentially expressed genes or proteins into known 
functions and pathways. Pathways with a z score of > 
+2 were considered as significantly activated, while 
pathways with a z score of < -2 were considered as 
significantly inhibited. 
 
Quantification and statistical analysis 
 
All analyses were performed with GraphPad Prism 6. 
Data were presented as mean ± SD (± SEM for OCR 
and ECAR profiles, see Figures 5 and 6). All 
experiments were conducted at least three times, with ≥ 
3 technical replicates per experiment, unless otherwise 
stated with representative data shown. Statistically 
significant differences were determined using the 
Student’s t test or the analysis of variance (ANOVA) 
test. For the comparison among multiple groups, one-
way ANOVA were used to determine statistical 
significance. P ≤ 0.05 was considered significant and all 
statistical tests were two-sided. 
 
Kaplan-Meier (K-M) analyses 
 
To perform K-M analysis on metabolic gene transcripts, 
we used an open-access online survival analysis tool to 
interrogate publically available microarray data from up 
to 3,455 breast cancer patients. This allowed us to 
determine their prognostic value. For this purpose, we 
primarily analyzed data from ER(+) patients that were 
LN(+) at diagnosis and were of the luminal A sub-type, 
that were primarily treated with tamoxifen and not other 
chemotherapy (N = 152 patients). In this group, 100% 
the patients received some form of hormonal therapy 
and ~95% of them received tamoxifen. Biased and 
outlier array data were excluded from the analysis. This 
allowed us to identify metabolic gene transcripts, with 
significant prognostic value. Hazard-ratios were calcu-
lated, at the best auto-selected cut-off, and p-values 
were calculated using the log-rank test and plotted in R.  
 
K-M curves were also generated online using the K-M-
plotter (as high-resolution TIFF files), using univariate 
analysis:  http://kmplot.com/analysis/index.php?p = 
service&cancer = breast. 
 
This allowed us to directly perform in silico validation 
of these metabolic biomarker candidates. The 2017 
version of the database was utilized for all these 
analyses, while virtually identical results were also 




ESR1: estrogen receptor alpha or estrogen receptor 1; 
TAMR: tamoxifen resistance cell line; 4-OHT: 4-
hydroxytamoxifen; ATP: adenosine triphosphate; WT: 
wild type; EV: empty vector; Y537S: estrogen receptor 
point mutation (tyrosine to serine); Y537N: estrogen 
receptor point mutation (tyrosine to asparagine); 
ERBB2: Erb-B2 receptor tyrosine kinase 2 (HER 2); 
CSC: cancer stem cell; OCR: oxygen consumption rate; 





MPL, FS and MF conceived and initiated this project. 
All experiments described in this paper were performed 
by MF, who then generated the final figures and tables 
for the paper; RSA also contributed experimental data. 
MPL and FS wrote the first draft of the manuscript, 
which was then further edited by MF and RSA. MPL 




We are grateful to the University of Manchester, which 
allocated start-up funds and administered a donation, to 
provide all the necessary resources required to start and 
complete this drug discovery project (to MPL and FS). 
We are tremendously grateful to Rumana Rafiq, for her 
kind and dedicated assistance, in keeping the 
Translational Medicine Laboratory at Salford running 
very smoothly. 
www.aging‐us.com  4013  AGING 
CONFLICTS OF INTEREST 
 





At the University of Salford, the Sotgia and Lisanti 
Laboratories are currently supported by the Foxpoint 
Foundation, the Healthy Life Foundation and the British 
Schools and Universities Foundation. Ongoing work is 







et  al.  ESR1  ligand‐binding  domain  mutations  in 





I.  D538G mutation  in  estrogen  receptor‐α:  A  novel 
mechanism  for  acquired  endocrine  resistance  in 
breast  cancer.  Cancer  Res.  2013;  73:6856–64. 
https://doi.org/10.1158/0008‐5472.CAN‐13‐1197 
3.   Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, 
Kalyana‐Sundaram  S,  Wang  R,  Ning  Y,  Hodges  L, 
Gursky A, Siddiqui J, Tomlins SA, et al. Activating ESR1 













6.   Smith  DB,  Howell  A, Wagstaff  J.  Infiltrating  lobular 
carcinoma  of  the  breast:  response  to  endocrine 
therapy  and  survival. Eur  J Cancer Clin Oncol. 1987; 
23:979–82. 
https://doi.org/10.1016/0277‐5379(87)90344‐0 
7.   Ribeiro  G,  Palmer  MK.  Adjuvant  tamoxifen  for 
operable  carcinoma  of  the  breast:  report  of  clinical 








9.  Jeselsohn  R,  Yelensky  R,  Buchwalter  G,  Frampton  G, 




pretreated  advanced  estrogen  receptor‐positive 




Taylor  DL,  Puhalla  SL,  et  al.  Clinically  Observed 
Estrogen  Receptor  Alpha  Mutations  within  the 
Ligand‐Binding  Domain  Confer  Distinguishable 
Phenotypes. Oncology. 2018; 94:176–89.  
  https://doi.org/10.1159/000485510 
11.  Weis  KE,  Ekena  K,  Thomas  JA,  Lazennec  G, 
Katzenellenbogen  BS.  Constitutively  active  human 










S,  Katzenellenbogen  BS,  Tajkhorshid  E,  Griffin  PR, 
Shen  Y,  et  al.  Estrogen  receptor  alpha  somatic 
mutations  Y537S  and  D538G  confer  breast  cancer 
endocrine  resistance  by  stabilizing  the  activating 
function‐2  binding  conformation.  eLife.  2016;  5:5. 
https://doi.org/10.7554/eLife.12792 
14.  Moreira PI, Custódio J, Moreno A, Oliveira CR, Santos 
MS. Tamoxifen and estradiol  interact with  the  flavin 








Cancer  Treatment.  Cancer  Res.  2016;  76:3295–306. 
https://doi.org/10.1158/0008‐5472.CAN‐15‐2197 
16.  Ozsvari B, Bonuccelli G, Sanchez‐Alvarez R, Foster R,  
www.aging‐us.com  4014  AGING 
Sotgia  F,  Lisanti  MP.  Targeting  flavin‐containing 
enzymes  eliminates  cancer  stem  cells  (CSCs),  by 
inhibiting  mitochondrial  respiration:  vitamin  B2 












Warburg  effect  kills  cancer  cells.  Cell  Cycle.  2011; 
10:2521–28. https://doi.org/10.4161/cc.10.15.16584 
19.  Toy W, Weir H,  Razavi  P,  Lawson M, Goeppert  AU, 
Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, 
De  Stanchina  E,  Carlson  KE,  Martin  TS,  et  al. 
Activating  ESR1  Mutations  Differentially  Affect  the 
Efficacy  of  ER  Antagonists.  Cancer  Discov.  2017; 
7:277–87.  https://doi.org/10.1158/2159‐8290.CD‐15‐
1523 
20.  Gelsomino  L,  Panza  S,  Giordano  C,  Barone  I,  Gu  G, 
Spina E, Catalano S, Fuqua S, Andò S. Mutations in the 
estrogen  receptor  alpha  hormone  binding  domain 
promote  stem  cell  phenotype  through  notch 







Bartrons  R,  Gottlieb  E,  Vousden  KH.  TIGAR,  a  p53‐
inducible  regulator  of  glycolysis  and  apoptosis.  Cell. 
2006; 126:107–20.  
  https://doi.org/10.1016/j.cell.2006.05.036 
23.  Li  H,  Jogl  G.  Structural  and  biochemical  studies  of 
TIGAR  (TP53‐induced  glycolysis  and  apoptosis 
regulator). J Biol Chem. 2009; 284:1748–54.  
  https://doi.org/10.1074/jbc.M807821200 
24.  Madan  E, Gogna  R,  Bhatt M,  Pati U,  Kuppusamy  P, 
Mahdi AA. Regulation of glucose metabolism by p53: 
emerging  new  roles  for  the  tumor  suppressor. 
Oncotarget. 2011; 2:948–57.  
  https://doi.org/10.18632/oncotarget.389 
25.  Martinez‐Outschoorn  UE,  Goldberg  A,  Lin  Z,  Ko  YH, 
Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell 
A,  Sotgia  F,  Lisanti  MP.  Anti‐estrogen  resistance  in 
breast  cancer  is  induced  by  the  tumor  micro‐
environment  and  can  be  overcome  by  inhibiting 
mitochondrial  function  in  epithelial  cancer  cells. 
Cancer Biol Ther. 2011; 12:924–38.  
  https://doi.org/10.4161/cbt.12.10.17780 
26.   Iyengar  P,  Espina  V,  Williams  TW,  Lin  Y,  Berry  D, 
Jelicks  LA,  Lee  H,  Temple  K,  Graves  R,  Pollard  J, 
Chopra  N,  Russell  RG,  Sasisekharan  R,  et  al. 
Adipocyte‐derived collagen VI affects early mammary 









Martinez‐Outschoorn  UE,  Sotgia  F,  Lisanti  MP. 
Antibiotics  that  target  mitochondria  effectively 
eradicate  cancer  stem  cells,  across  multiple  tumor 




Smith  DL,  Clarke  RB,  Howell  SJ,  Cappello  AR, 
Martinez‐Outschoorn  UE,  Peiris‐Pagès  M,  Sotgia  F, 
Lisanti MP. Doxycycline down‐regulates DNA‐PK and 
radiosensitizes  tumor  initiating cells:  implications  for 
more  effective  radiation  therapy. Oncotarget.  2015; 
6:14005–25. 
https://doi.org/10.18632/oncotarget.4159 
30.  Sotgia  F,  Ozsvari  B,  Fiorillo  M,  De  Francesco  EM, 
Bonuccelli  G,  Lisanti  MP.  A  mitochondrial  based 
oncology  platform  for  targeting  cancer  stem  cells 
(CSCs): MITO‐ONC‐RX. Cell Cycle. 2018; 17:2091–100. 
https://doi.org/10.1080/15384101.2018.1515551 
31.  Fiorillo  M,  Lamb  R,  Tanowitz  HB,  Mutti  L,  Krstic‐
Demonacos  M,  Cappello  AR,  Martinez‐Outschoorn 
UE,  Sotgia  F,  Lisanti  MP.  Repurposing  atovaquone: 
targeting mitochondrial  complex  III  and OXPHOS  to 
eradicate  cancer  stem  cells.  Oncotarget.  2016; 
7:34084–99. 
https://doi.org/10.18632/oncotarget.9122 
32.  Fiorillo  M,  Lamb  R,  Tanowitz  HB,  Cappello  AR, 
Martinez‐Outschoorn  UE,  Sotgia  F,  Lisanti  MP. 
Bedaquiline,  an  FDA‐approved  antibiotic,  inhibits 
mitochondrial  function  and  potently  blocks  the 




HB,  Lisanti  MP.  NADH  autofluorescence,  a  new 
www.aging‐us.com  4015  AGING 
metabolic  biomarker  for  cancer  stem  cells: 
identification  of  Vitamin  C  and  CAPE  as  natural 





lethal  combination  therapy  targeting  metabolic 
flexibility  in  cancer  stem  cells  (CSCs).  Oncotarget. 
2017; 8:67269–86.  
  https://doi.org/10.18632/oncotarget.18428 
35.  Scatena  C,  Roncella  M,  Di  Paolo  A,  Aretini  P, 
Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli 
M,  Sotgia  F,  Lisanti MP, Naccarato AG. Doxycycline, 
an  Inhibitor  of Mitochondrial  Biogenesis,  Effectively 
Reduces  Cancer  Stem  Cells  (CSCs)  in  Early  Breast 
Cancer  Patients:  A  Clinical  Pilot  Study.  Front Oncol. 
2018; 8:452.  
  https://doi.org/10.3389/fonc.2018.00452 
36.  Shaw  FL,  Harrison  H,  Spence  K,  Ablett MP,  Simões 
BM,  Farnie  G,  Clarke  RB.  A  detailed mammosphere 







cancer  stem  cells  (CSCs)  by  targeting  mevalonate, 




J, Di  Y, McGinn OJ,  Fiorillo M,  Sotgia  F,  Lisanti MP, 
Parihar  M,  Krishnan  S,  Saha  V.  Metabolic 




39.  Lamb  R,  Bonuccelli  G,  Ozsvári  B,  Peiris‐Pagès  M, 
Fiorillo  M,  Smith  DL,  Bevilacqua  G,  Mazzanti  CM, 
McDonnell  LA,  Naccarato  AG,  Chiu  M,  Wynne  L, 
Martinez‐Outschoorn UE, et al. Mitochondrial mass, a 
new metabolic biomarker  for  stem‐like  cancer  cells: 




DL,  Sanchez‐Alvarez  R,  Martinez‐Outschoorn  UE, 
Cappello  AR,  Pezzi  V,  Lisanti  MP,  Sotgia  F. 
Mitochondrial  biogenesis  is  required  for  the  ancho‐
rage‐independent  survival  and propagation of  stem‐
like  cancer  cells.  Oncotarget.  2015;  6:14777–95. 
https://doi.org/10.18632/oncotarget.4401 
41.  Peiris‐Pagès M, Smith DL, Győrffy B, Sotgia F, Lisanti 
MP.  Proteomic  identification  of  prognostic  tumour 
biomarkers,  using  chemotherapy‐induced  cancer‐


















































































































































cancer MCF7‐Y537S cells.  (A) Canonical pathways predicted  to be altered  in MCF7‐Y537S Vs MCF7‐EV‐Lv105 are shown. As




and PTEN  signaling pathways  that were up‐regulated.  The pvalue  (p  <  0.05)  for  each pathway  is  indicated by  the bar  and  is
expressed  as  −1  times  the  log of  the p‐value. A positive  z‐score  (Orange  color;  z‐score > 2)  represents  the upregulation of  a
specific pathway, while a negative z‐score (Blue color; z‐score < 2) indicates the down‐regulation of a pathway. 











































































































































































































































Analysis showed  that certain  toxicity  functions are significantly enriched by  the proteins
differentially expressed  in  this comparative analysis  (p < 0.05).  In  the Stacked Bar chart,
the p‐value for each pathway is indicated by the bar and is expressed as −1 times the log
of  the p‐value  (cutoff  z‐score ± 2).In  red color  the amount of  the proteins up‐regulated
and in green color the amount of the proteins down‐regulated in each patwhays. 
 




























































































obtained  from  human  breast  cancer MCF7‐Y537S  cells  compared  to MCF7‐ESRI.
Canonical pathways predicted  to be altered  in MCF7‐Y537S Vs MCF7‐ESRI  in presence of 4‐
OHT (1 µM) are shown. As expected, certain canonical pathways were significantly altered by
the  differential  protein  expression  in  MCF7‐Y537S  respect  MCF7‐ESRI.  In  particular,  in
presence of 4‐OHT  (1 µM), all  the  resulting pathways  in MCF7‐Y537S were down‐regulated
compared to MCF7‐ESRI, except for RhoGDI signaling pathway that was down‐regulated. 
 


















































































































Symbol                Description         Fold-Change (Up-regulation) 
 
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial      110.11 
HIBADH  3-hydroxyisobutyrate dehydrogenase, mitochondrial                   54.89 
NDUFB10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit    49.59 
PGAM5               Serine/threonine-protein phosphatase PGAM5, mitochondrial                  8.80 
MRPL47 39S ribosomal protein L47, mitochondrial       8.27 
ACSS1               Acetyl-coenzyme A synthetase 2-like, mitochondrial                   7.15 
FH   Fumarate hydratase, mitochondrial        6.68 
HSPD1               60 kDa heat shock protein, mitochondrial       6.02 
OGDH                2-oxoglutarate dehydrogenase E1 component, mitochondrial                  5.44 
MRPL4               39S ribosomal protein L4, mitochondrial       4.54 
GRPEL1 GrpE protein homolog 1, mitochondrial       4.48 
ISOC2  Isochorismatase domain-containing protein 2, mitochondrial                  3.80 
DUT   Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial   2.93 
SDHB   Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial   2.75 
NDUFV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial    2.74 
ECSIT   Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial               2.70 
GATC   Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial   2.68 
PTRH2               Peptidyl-tRNA hydrolase 2, mitochondrial      2.35 
DNAJA3 DnaJ homolog subfamily A member 3, mitochondrial                  2.14 
AKAP1               A-kinase anchor protein 1, mitochondrial      2.07 
HSPA9                Stress-70 protein, mitochondrial        2.04 
FDXR  NADPH:adrenodoxin oxidoreductase, mitochondrial                   1.99 
TIMM23B  Putative mitochondrial import inner membrane translocase subunit Tim23B               1.95 
COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial     1.94 
NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5   1.93 
CLUH   Clustered mitochondria protein homolog      1.88 
GLS   Glutaminase kidney isoform, mitochondrial      1.85 
ABCB6               ATP-binding cassette sub-family B member 6, mitochondrial                  1.85  
PPA2  Inorganic pyrophosphatase 2, mitochondrial      1.83 
MRPL43 39S ribosomal protein L43, mitochondrial       1.70 
MRPS16 28S ribosomal protein S16, mitochondrial       1.69 
MRPL15 39S ribosomal protein L15, mitochondrial       1.64 
MRPS18B  28S ribosomal protein S18B, mitochondrial       1.60 
 
Proteins highlighted in BOLD are involved in mitochondrial biogenesis.  


















































































































Symbol                Description                       Fold-Change (Up-regulation) 
 
COL6A3 Collagen, type VI, alpha 3                     Infinity 
ERBB2                Erb-b2 avian erythroblastic leukemia viral oncoprotein 2                 14,233.50 
STAT3  Signal transducer and activator of transcription 3                  28.56 
AFP  Alpha-fetoprotein                     12.07 
TFF1   Trefoil factor 1                      3.92 
CDK4  Cyclin-dependent kinase 4, isoform                   2.82 
CD44  CD44 antigen                     1.98 
Table S4. Y537S targets are transcriptionally up‐regulated in breast cancer cells in vivo (Epithelia vs. Tumor Stroma). 
Symbol                Gene Description                     Up-regulation  P-value 
                                                                                                                                                                           (Fold-Change) 
Mitochondrial components 
 
FH   Fumarate hydratase, mitochondrial        5.42  7.06E-07 
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial      4.84  5.73E-0  
SDHB   Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial   4.25  4.24E-05 
HSPA9                Stress-70 protein, mitochondrial        3.69  2.64E-04 
MRPS18B  28S ribosomal protein S18B, mitochondrial       3.65  2.94E-04 
HSPD1               60 kDa heat shock protein, mitochondrial       3.42  5.93E-04 
COX4I1               Cytochrome c oxidase subunit 4 isoform 1, mitochondrial     3.39  6.61E-04 
AKAP1  A-kinase anchor protein 1, mitochondrial      3.33  7.75E-04 
PPA2  Inorganic pyrophosphatase 2, mitochondrial      3.19  1.17E-03 
DNAJA3 DnaJ homolog subfamily A member 3, mitochondrial                  2.92  2.57E-03 
PTRH2               Peptidyl-tRNA hydrolase 2, mitochondrial      2.77  3.82E-03 
NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5   2.75  4.07E-03 
GRPEL1 GrpE protein homolog 1, mitochondrial       2.39  1.01E-02 
MRPL15 39S ribosomal protein L15, mitochondrial       2.26  1.39E-02 
DUT   Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial   1.87  3.37E-02 
GLS   Glutaminase kidney isoform, mitochondrial      1.81  3.81E-02 
 
Table S2. Glycolysis and PPP‐related proteins induced by the ESR1 (Y537S) mutant, as compared with ESR1‐WT.
Symbol               Description          Fold-Change (Up-regulation) 
 
TIGAR                Fructose-2,6-bisphosphatase (TIGAR)       Infinity  
ENO2  Gamma-enolase          128.23 
GAPDH   Glyceraldehyde-3-phosphate dehydrogenase      7.41 
PKM  Pyruvate kinase          7.41 
PHGDHL1 Phosphoglycerate dehydrogenase like 1       4.51 
PFKP  Phosphofructokinase, platelet        3.08 
ENO1  Enolase           3.07 
TALDO1 Transaldolase          2.30 
G6PD   Glucose-6-phosphate 1-dehydrogenase       2.19 



















































































































Symbol    Probe  RFS-HR  Log-Rank Test 
       
HSPD1    200807_s_at   3.40  1.2e-05 
HSPD1    200806_s_at  2.36  0.0035 
MRPL15    218027_at  3.20  1.7e-05 
MRPL4     218105_s_at  2.20  0.005 
AKAP1    210626_at  2.19  0.007 
AKAP1    201674_s_at  1.90  0.025 
PTRH2    218732_at  2.17  0.005 
COX4I1    202698_x_at  2.04  0.049 
GRPEL1    212434_at  2.01  0.012 
HSPA9     200691_s_at  1.97  0.024 






Symbol  Probe  RFS-HR  Log-Rank Test 
       
ENO1  201231_s_at  2.28  0.004 
TALDO1  201463_s_at  2.14  0.014 
TIGAR   219099_at   2.13  0.008 








TALDO1 Transaldolase          4.13  6.35E-05 
PKM2  Pyruvate kinase 2         3.26  9.79E-04 
GAPDH               Glyceraldehyde-3-phosphate dehydrogenase                   2.97  2.22E-  
ENO1  Enolase             1.96  2.75E-02 
 
Cell signalling molecules 
 
CD44  CD44 antigen                      3.44                 5.69E-0 
CDK4  Cyclin-dependent kinase 4, isoform                    2.33                 1.19E-02 
TFF1  Trefoil factor 1          1.76  4.17E-02
           
Transcriptional  profiling  data  derived  from  the  analysis  of  N=28  breast  cancer  patients  are  shown,  high‐lighting  the  levels  of  fold‐
upregulation observed in the epithelial cancer cell compartment (relative to the tumor stroma), and corresponding p‐values derived from 
the analysis of these clinical samples. 



















































Symbol  Probe       DMFS-HR                Log-Rank Test 
      
ENO2  201313_at      2.70              0.0035 







Symbol   Probe    DMFS-HR   Log-Rank Test 
       
HSPD1   200807_s_at     3.47  9e-05 
HSPD1   200806_s_at    2.03  0.03 
GRPEL1   212434_at    3.18  0.004 
MRPL15   218027_at    2.57  0.0035 
MRPS16    218046_s_at    2.53  0.006 
COX4I1   202698_x_at    2.26   0.013 
 
DMFS, distant metastasis‐free survival. 
HR, hazard‐ratio. 
 
